Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alteogen Inc (196170)
Alteogen Inc stock price live, this page displays KQ 196170 stock exchange data. View the 196170 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alteogen Inc real time stock price chart below.
What Is the Alteogen Inc Stock Price Today?
The Alteogen Inc stock price today is 337,000.
What Is the Stock Symbol for Alteogen Inc?
The stock symbol for Alteogen Inc is "196170."
What Stock Exchange Does Alteogen Inc Trade On?
Alteogen Inc is listed and trades on the KOSDAQ stock exchange.
Is Alteogen Inc a Good Stock to Buy?
Determining whether Alteogen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 196170 quote. (ISIN: KR7196170005)
What Is the Alteogen Inc Stock Price Today?
The Alteogen Inc stock price today is 337,000.
What Is the Stock Symbol for Alteogen Inc?
The stock symbol for Alteogen Inc is "196170."
What Stock Exchange Does Alteogen Inc Trade On?
Alteogen Inc is listed and trades on the KOSDAQ stock exchange.
Is Alteogen Inc a Good Stock to Buy?
Determining whether Alteogen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 196170 quote. (ISIN: KR7196170005)
337,000
-10,000(-2.88%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
333,000
358,000
52 wk Range
286,000
569,000
196170 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
333,000358,000
52 wk Range
286,000569,000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
196170 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
464,000
Upside
+37.69%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alteogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 464,000
(+37.69% Upside)
Earnings
Latest Release
May 08, 2026
EPS / Forecast
903.49 / 700.05
Revenue / Forecast
75.91B / 88.41B
Compare 196170 to Peers and Sector
Metrics to compare | 196170 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship196170PeersSector | |
|---|---|---|---|---|
P/E Ratio | 138.6x | −18.3x | −0.5x | |
PEG Ratio | −8.85 | 0.19 | 0.00 | |
Price/Book | 35.8x | 2.2x | 2.6x | |
Price / LTM Sales | 88.6x | 5.8x | 3.0x | |
Upside (Analyst Target) | 48.4% | 42.4% | 58.6% | |
Fair Value Upside | Unlock | 15.7% | 10.2% | Unlock |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alteogen (196170) Stock Price Today?
The Alteogen stock price today is 337,000 KRW.
What Stock Exchange Does Alteogen Trade On?
Alteogen is listed and trades on the KOSDAQ.
What Is the Stock Symbol for Alteogen?
The stock symbol for Alteogen is "196170."
Does Alteogen Pay Dividends? What’s The Current Dividend Yield?
The Alteogen dividend yield is 0.11%.
What Is the Alteogen Market Cap?
As of today, Alteogen market cap is 18.05T KRW.
What Is Alteogen's Earnings Per Share (TTM)?
The Alteogen EPS (TTM) is 1,960.
When Is the Next Alteogen Earnings Date?
Alteogen will release its next earnings report on Aug 19, 2026.
From a Technical Analysis Perspective, Is 196170 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Alteogen Stock Split?
Alteogen has split 4 times.
How Many Employees Does Alteogen Have?
Alteogen has 172 employees.
What is the current trading status of Alteogen (196170)?
As of Jun 13, 2026, Alteogen (196170) is trading at a price of 337,000 KRW, with a previous close of 347,000 KRW. The stock has fluctuated within a day range of 333,000 KRW to 358,000 KRW, while its 52-week range spans from 286,000 KRW to 569,000 KRW.
What Is Alteogen (196170) Price Target According to Analysts?
The average 12-month price target for Alteogen is 464,000 KRW, with a high estimate of 620000 KRW and a low estimate of 250000 KRW. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +37.69% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.